Grace Therapeutics secures $10 million private placement to fund operations through end‑2028
Executive summary: Grace Therapeutics closed a $10 million private placement on August 5 2026. The proceeds are projected to cover operational expenses through the end of 2028, alleviating immediate funding needs.
Who is involved: Grace Therapeutics (issuer) and undisclosed accredited investors participating in the placement.
Likely next: The company will file the required Form D with the SEC within 15 days and allocate the capital to its research and development programs.
Grace Therapeutics announced a $10 million private placement, stating that the gross proceeds are expected to extend the company’s cash runway to the end of calendar 2028. The placement is a typical Regulation D offering that provides immediate working capital without the dilution of a public offering. By lengthening its cash runway, the company reduces near‑term financing pressure and can continue advancing its pipeline.
Timeline
- — Grace Therapeutics Announces $10 Million Private Placement (GlobeNewswire)
- — Attovia Therapeutics Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)